Effects of omeprazole on plasma levels of raltegravir.
Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with omeprazole coadministration in healthy subjects; this is likely secondary to an increase in bioavailability attributable to increased gastric pH. Increased gastric pH has been reported in HIV-1-infected individuals, and the effects of omeprazole in this intended population may be diminished. Further investigation is necessary.
Iwamoto
Marian
M
Merck & Co., Whitehouse Station, Rahway, NJ 07065-0900, USA. marian_iwamoto@merck.com
Wenning
Larissa A
LA
Nguyen
Bach-Yen
BY
Teppler
Hedy
H
Moreau
Allison R
AR
Rhodes
Rand R
RR
Hanley
William D
WD
Jin
Bo
B
Harvey
Charlotte M
CM
Breidinger
Sheila A
SA
Azrolan
Neal
N
Farmer
H Frank
HF
Isaacs
Robin D
RD
Chodakewitz
Jeffery A
JA
Stone
Julie A
JA
Wagner
John A
JA
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000493:pharmacokinetics* / Q000627:therapeutic use; D010949:Plasma / Q000737:chemistry*; D011760:Pyrrolidinones / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D055815:Young Adult
D019380:Anti-HIV Agents; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D009853:Omeprazole